Your browser doesn't support javascript.
loading
Clinical standards for the management of adverse effects during treatment for TB.
Singh, K P; Carvalho, A C C; Centis, R; D Ambrosio, L; Migliori, G B; Mpagama, S G; Nguyen, B C; Aarnoutse, R E; Aleksa, A; van Altena, R; Bhavani, P K; Bolhuis, M S; Borisov, S; van T Boveneind-Vrubleuskaya, N; Bruchfeld, J; Caminero, J A; Carvalho, I; Cho, J G; Davies Forsman, L; Dedicoat, M; Dheda, K; Dooley, K; Furin, J; García-García, J M; Garcia-Prats, A; Hesseling, A C; Heysell, S K; Hu, Y; Kim, H Y; Manga, S; Marais, B J; Margineanu, I; Märtson, A-G; Munoz Torrico, M; Nataprawira, H M; Nunes, E; Ong, C W M; Otto-Knapp, R; Palmero, D J; Peloquin, C A; Rendon, A; Rossato Silva, D; Ruslami, R; Saktiawati, A M I; Santoso, P; Schaaf, H S; Seaworth, B; Simonsson, U S H; Singla, R; Skrahina, A.
Afiliación
  • Singh KP; Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Victorian Infectious Disease Unit, Royal Melbourne Hospital, VIC, Australia.
  • Carvalho ACC; Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
  • Centis R; Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
  • D Ambrosio L; Public Health Consulting Group, Lugano, Switzerland.
  • Migliori GB; Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
  • Mpagama SG; Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania, Kibong´oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania.
  • Nguyen BC; Woolcock Institute of Medical Research, Viet Nam and University of Sydney, NSW, Australia.
  • Aarnoutse RE; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Aleksa A; Grodno State Medical University, Grodno, Belarus.
  • van Altena R; Asian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM), Yangon, Myanmar.
  • Bhavani PK; Indian Council of Medical Research-National Institute for Research in Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Bolhuis MS; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Borisov S; Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia.
  • van T Boveneind-Vrubleuskaya N; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands.
  • Bruchfeld J; Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Caminero JA; Department of Pneumology. University General Hospital of Gran Canaria "Dr Negrin", Las Palmas, Spain, ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain.
  • Carvalho I; Paediatric Department, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia, Portugal.
  • Cho JG; Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Parramatta Chest Clinic, Parramatta, NSW, Australia.
  • Davies Forsman L; Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Dedicoat M; Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Dheda K; Centre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa, South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Af
  • Dooley K; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Furin J; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
  • García-García JM; Tuberculosis Research Programme, SEPAR (Sociedad Española de Neumología y Cirugía Torácica), Barcelona, Spain.
  • Garcia-Prats A; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa, Department of Pediatrics, University of Wisconsin, Madison, WI, USA.
  • Hesseling AC; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
  • Heysell SK; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
  • Hu Y; Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
  • Kim HY; Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
  • Manga S; Tuberculosis Department Latin American Society of Thoracic Diseases, Lima, Peru.
  • Marais BJ; Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Department of Infectious Diseases and Microbiology, The Children´s Hospital at Westmead, Westmead, NSW, Australia.
  • Margineanu I; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Märtson AG; Centre of Excellence in Infectious Diseases Research, Antimicrobial Pharmacodynamics and Therapeutics Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • Munoz Torrico M; Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, México City, Mexico.
  • Nataprawira HM; Division of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
  • Nunes E; Department of Pulmonology of Central Hospital of Maputo, Maputo, Mozambique, Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique.
  • Ong CWM; Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scien
  • Otto-Knapp R; German Central Committee Against Tuberculosis (DZK), Berlin, Germany.
  • Palmero DJ; Hospital Muniz and Instituto Vaccarezza, Buenos Aires, Argentina.
  • Peloquin CA; Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
  • Rendon A; Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Neumología, CIPTIR, Monterrey, Mexico.
  • Rossato Silva D; Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
  • Ruslami R; TB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
  • Saktiawati AMI; Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia, Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Santoso P; Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.
  • Schaaf HS; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
  • Seaworth B; University of Texas Health Science Center at Tyler, Tyler, TX, USA.
  • Simonsson USH; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
  • Singla R; Department of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India.
  • Skrahina A; Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
Int J Tuberc Lung Dis ; 27(7): 506-519, 2023 Jul 01.
Article en En | MEDLINE | ID: mdl-37353868
ABSTRACT

BACKGROUND:

Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.

METHODS:

65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.

RESULTS:

We identified eight clinical standards. Each person commencing treatment for TB should Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.

CONCLUSION:

These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Hipersensibilidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tuberculosis / Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos / Hipersensibilidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article